HUTCHMED Highlights Phase III SANOVO Data at ESMO Congress
HUTCHMED said ORPATHYS plus TAGRISSO reduced the risk of disease progression or death by 44% in the overall population. The data were presented at the ESMO Congress 2026.
HUTCHMED said ORPATHYS plus TAGRISSO reduced the risk of disease progression or death by 44% in the overall population. The data were presented at the ESMO Congress 2026.